Pharmacological evaluation of novel 5-HT₃ receptor antagonist, QCM-13 (N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) as anti-anxiety agent in behavioral test battery

Medicine & Life Sciences

• Anti-Anxiety Agents 44%
• Anxiety Disorders 11%
• Behavior Rating Scale 46%
• Buspirone 8%
• Diazepam 6%
• Light 4%
• N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide 100%
• Pharmaceutical Preparations 2%
• Pharmacology 26%
• Piperazine 24%
• Receptor, Serotonin, 5-HT2A 7%
• Receptors, Serotonin, 5-HT3 52%
• Rodentia 4%
• Serotonin 5-HT1 Receptor Agonists 7%
• Serotonin 5-HT3 Receptor Antagonists 55%
• Therapeutics 1%

Chemical Compounds

• Agent Interacting With Transmitter, Hormone or Drug Receptor 11%
• Anxiogenic 19%
• Anxiolytic Agent 55%
• Buspirone 16%
• Diazepam 12%
• Disorder 17%
• Dose 7%
• Drug 5%
• Piperazine 32%
• Serotonin 11%
• Serotonin 1A Agonist 17%
• Serotonin 5-HT3 Receptor Antagonist 64%